Universal reference book for medicines
Product name: BALUTAR

Active substance: bicalutamide

Type: Antiandrogenic non-steroid drug with antitumor activity

Manufacturer: TAD PHARMA (Germany) manufactured by GENEPHARM (Greece)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
Antiandrogenic nonsteroid agent.
Linking to receptors that have an affinity for androgens, suppresses the activity of androgens, as a result of which regression of the tumor of the prostate gland is observed. Does not have other kinds of endocrine activity.
PHARMACOKINETICS
After oral administration, it is well absorbed from the digestive tract.
Eating does not affect bioavailability.
Binding to plasma proteins is 96%.
Intensively metabolized in the liver by oxidation and the formation of glucuronide conjugates.
It is excreted in the form of metabolites with urine and bile approximately in equal proportions.

Possible cumulation of bicalutamide in the body.

INDICATIONS
Prostate cancer - as part of a combination therapy with an analogue of GnRH or with surgical castration.

DOSING MODE
Individual, depending on the indications and treatment regimen.

SIDE EFFECT
From the endocrine system: tides, tenderness of the mammary glands and gynecomastia, decreased libido.

On the part of the digestive system: abdominal pain, diarrhea, nausea, vomiting, increased levels of transaminases, jaundice, cholestasis.

From the side of the central nervous system: asthenia, depression are possible.

Dermatological reactions: alopecia, restoration of hair growth, itching, dry skin.

Other: hematuria.

CONTRAINDICATIONS
Simultaneous reception with terfenadine, astemizole, cisapride;
children's age, hypersensitivity to bicalutamide.
Do not prescribe to female patients.

PREGNANCY AND LACTATION
Do not prescribe to female patients.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in patients with moderately severe and severe impairment of liver function.
the cumulation of bicalutamide in the body is possible.
During the period of treatment, regular monitoring of liver function is required.
In the case of severe changes, bicalutamide should be discontinued.
APPLICATION FOR CHILDREN
The drug is not prescribed for children.

SPECIAL INSTRUCTIONS
Use with caution in patients with moderately severe and severe impairment of liver function.
the cumulation of bicalutamide in the body is possible.
During the period of treatment, regular monitoring of liver function is required.
In the case of severe changes, bicalutamide should be discontinued.
DRUG INTERACTION
When bicalutamide was used for 28 days with midazolam, the midazolam AUC increased by 80%.

With the simultaneous use of bicalutamide with cyclosporine or calcium channel blockers, potentiation or development of unwanted reactions is possible.

Theoretically, it is possible to increase the concentration of bicalutamide in blood plasma when it is used simultaneously with inhibitors of microsomal enzymes of the liver, which may be accompanied by an increase in the incidence of undesirable reactions.

In vitro studies have shown that bicalutamide can displace the coumarin anticoagulant warfa
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!